Communiqués BioXcel Therapeutics, Inc.

Actions

BTAI

US09075P1057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2024			Varia. 5j.	Varia. 1 janv.
1,46 ^USD	+2,10 %		-10,43 %	-50,51 %

09/05	BioXcel Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioXcel Therapeutics : Submission of Matters to a Vote of Security Holders Form 8 K	12/06	PU
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference	28/05	AQ
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	22/05	AQ
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting	21/05	AQ
BioXcel Therapeutics Reports First Quarter 2024 Financial Results	09/05	AQ
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	25/04	AQ
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	24/04	AQ
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22/04	AQ
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	10/04	AQ
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	25/03	AQ
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	15/03	AQ
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	12/03	AQ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	01/03	AQ
BioXcel Therapeutics Announces Termination of Proposed Public Offering	13/02	AQ
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)	12/02	AQ
BioXcel Therapeutics Announces Proposed Public Offering	08/02	AQ
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®	06/02	AQ
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine	05/02	AQ
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today	12/12	AQ
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs	11/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioXcel Therapeutics, Inc.

Actions

BTAI

US09075P1057

Communiqués

Filtres